Healthcare stocks fade as obesity-drug optimism fades
By Dow Jones Newswires
Healthcare companies fell sharply Monday as ebullience about a new class of weight control drugs subsided.
Viking Therapeutics shares (VKTX) gave back some of their recent gains amid skepticism about the biotech firm's attempt to compete with heavyweights such as Novo Nordisk on obesity drugs. Novo Nordisk (NVO) fell, shaving its gains for the year to date to around 25%.
Shares of Eiger BioPharmaceuticals (EIGR) plunged after the drug developer filed for chapter 11 bankruptcy with a deal in hand to sell its Zokinvy drug.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
04-01-24 2059ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks